| Literature DB >> 27057160 |
Yi-Zuo Song1, He-Yi You1, Zhe-Hui Zhu1, Zheng-De Wen1, Hui-Ying Xu1, Bi-Cheng Chen1, Zong-Jing Chen1, Qing-Ke Huang2.
Abstract
Background. Functional dyspepsia (FD) is a functional upper gastrointestinal disorder with significant morbidity and medical costs. Previous studies investigated the association of G-protein β3 (GNB3) genetic polymorphisms with FD but with inconsistent results. Therefore, we performed a meta-analysis to derive a precise estimation of the relationship between GNB3 polymorphisms and FD. Methods. We searched different databases including PubMed, EMBASE, CNKI, and the Ovid Library to gather eligible studies on GNB3 polymorphisms and FD. The association was assessed by the odds ratio (OR) with 95% confidence intervals (CI). Results. We identified 12 studies with 1109 cases and 2853 controls for the analysis. We found no associations of GNB3 C825T polymorphism with FD in the overall population (T versus C, OR = 1.06, 95% CI: 0.96-1.18, P = 0.26; TT versus CC + CT, OR = 1.16, 95% CI: 0.97-1.39, P = 0.11; TT + CT versus CC, OR = 1.01, 95% CI: 0.77-1.31, P = 0.96; TT versus CC, OR = 1.15, 95% CI: 0.93-1.44, P = 0.20). Subgroup analyses by genotyping method indicated that the magnitude of association was strengthened for additive model (OR = 1.15, 95% CI: 1.07-2.24, P = 0.02). Sensitivity analysis did not reveal significant associations under all models. Conclusions. This meta-analysis demonstrates that GNB3 C825T polymorphism may not be a risk factor for FD.Entities:
Year: 2015 PMID: 27057160 PMCID: PMC4736015 DOI: 10.1155/2016/5037254
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Figure 1The flow diagram of the selection of studies.
Characteristics of included studies in the meta-analysis.
| Author | Year | Country | Ethnicity |
Mean age |
Gender | Definition of FD | Genotyping method | Functional dyspepsia | Controls | HWE | NOS Score | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | CC | CT | TT | Total | CC | CT | TT | ||||||||||
|
Holtmann et al. [ | 2004 | America | American | 46.4 ± 1.9/44.4 ± 1.3 | 60/108 | Rome II | PCR-RFLP | 56 | 34 | 18 | 4 | 112 | 46 | 62 | 4 | 0 |
|
|
Camilleri et al. [ | 2006 | America | Caucasian | 55/60 | 44/45 | Rome II | Direct sequencing | 50 | 32 | 10 | 8 | 39 | 17 | 21 | 1 | 0.07 |
|
|
Li et al. [ | 2006 | China | Chinese | 48.9 ± 9.9/46.2 ± 8.9 | 112/132 | Rome II | PCR-RFLP | 102 | 21 | 41 | 40 | 142 | 38 | 55 | 49 | 0.01 |
|
|
Tahara et al. [ | 2008 | Japan | Japanese | 60.1 ± 13.1/61.1 ± 13.1 | 130/53 | Rome II | PCR-RFLP | 89 | 20 | 38 | 31 | 94 | 23 | 48 | 23 | 0.84 |
|
|
van Lelyveld et al. [ | 2008 | Netherlands | Caucasian | 42.3 ± 1/41.9 ± 1 | 115/333 | Rome II | Molecular beacon assay | 112 | 48 | 54 | 10 | 336 | 180 | 126 | 30 | 0.25 |
|
|
de Vries et al. [ | 2009 | America | American | 49.7 ± 12.3/40.1 ± 12.3 | 182/319 | Rome II | Molecular beacon assay | 128 | 60 | 56 | 12 | 373 | 199 | 138 | 36 | 0.1 |
|
|
Oshima et al. [ | 2010 | Japan | Japanese | 43/45 | 350/479 | Rome III | TaqMan Assay | 68 | 17 | 29 | 22 | 761 | 191 | 368 | 202 | 0.37 |
|
|
Shimpuku et al. [ | 2011 | Japan | Japanese | 59.2 ± 14.2/37.2 ± 9.13 | 93/45 | Rome III | Direct sequencing | 74 | 14 | 44 | 16 | 64 | 17 | 28 | 19 | 0.32 |
|
| Kim et al. [ | 2012 | Korea | Korean | 49 ± 15/47 ± 15 | 229/372 | Rome III | TaqMan Assay | 167 | 52 | 76 | 39 | 434 | 112 | 215 | 107 | 0.85 |
|
|
Park and Uhm [ | 2012 | Korea | Korean | 11.2 ± 3.6/10.8 ± 3.9 | 113/137 | Rome III | Single base primer extension assay | 102 | 37 | 39 | 26 | 148 | 35 | 79 | 34 | 0.41 |
|
|
Chung et al. [ | 2014 | Korea | Korean | 46.8 ± 15.7/50.5 ± 11.1 | 62/69 | Rome III | PCR-RFLP | 50 | 5 | 27 | 18 | 81 | 15 | 51 | 15 | 0.02 |
|
|
Hwang et al. [ | 2014 | Korea | Korean | 50/54 | 147/234 | Rome III | PCR-RFLP | 111 | 20 | 62 | 29 | 269 | 64 | 132 | 73 | 0.77 |
|
HWE, Hardy-Weinberg equilibrium; NOS, Newcastle-Ottawa Scale.
Figure 2The forest plot for the associations of GNB3 C825T polymorphism and FD risk based on overall analysis. (a) For additive model (CC versus TT). (b) For recessive model (CT + TT versus CC). (c) For dominant model (CC + CT versus TT). (d) For allelic model (C versus T).
Meta-analysis of the association between GNB3 gene C825T polymorphism and functional dyspepsia risk.
| Comparisons | OR (95% CI) |
|
| Egger's test |
|---|---|---|---|---|
| CC versus TT | ||||
| Overall | 1.15 (0.93–1.44) | 0.20 | 0 |
|
| Asia | 1.12 (0.87–1.43) | 0.37 | 18% |
|
| America | 1.34 (0.74–2.42) | 0.34 | 0 | 0.291 |
| Rome II | 1.40 (0.98–1.98) | 0.06 | 0 | 0.147 |
| Rome III | 1.02 (0.77–1.35) | 0.87 | 27% | 0.101 |
| PCR-RFLP | 1.55 (1.07–2.24) |
| 0 | 0.320 |
| HWE | 1.06 (0.84–1.35) | 0.63 | 0 |
|
| IBS | 1.16 (0.92–1.46) | 0.21 | 1% |
|
| NOS Score | 1.12 (0.87–1.43) | 0.38 | 15% |
|
| CC + CT versus TT | ||||
| Overall | 1.16 (0.97–1.39) | 0.11 | 12% | 0.057 |
| Asia | 1.14 (0.94–1.39) | 0.19 | 19% | 0.304 |
| America | 1.40 (0.80–2.44) | 0.24 | 46% | 0.097 |
| Rome II | 1.32 (0.98–1.77) | 0.07 | 0 | 0.126 |
| Rome III | 1.08 (0.86–1.35) | 0.53 | 29% | 0.475 |
| PCR-RFLP | 1.33 (1.00–1.77) | 0.05 | 19% | 0.171 |
| HWE | 1.08 (0.88–1.32) | 0.44 | 0 | 0.180 |
| IBS | 1.17 (0.97–1.41) | 0.10 | 19% | 0.052 |
| NOS Score | 1.15 (0.94–1.41) | 0.17 | 31% | 0.103 |
| CT + TT versus CC | ||||
| Overall | 1.01 (0.77–1.31) | 0.96 | 59% | 0.818 |
| Asia | 1.00 (0.82–1.23) | 0.97 | 42% | 0.078 |
| America | 0.67 (0.30–1.50) | 0.33 | 80% | 0.215 |
| Rome II | 0.99 (0.66–1.49) | 0.96 | 67% | 0.098 |
| Rome III | 1.00 (0.70–1.43) | 0.99 | 52% | 0.157 |
| PCR-RFLP | 1.11 (0.69–1.80) | 0.67 | 59% | 0.790 |
| HWE | 1.02 (0.77–1.34) | 0.91 | 56% | 0.603 |
| IBS | 0.98 (0.73–1.31) | 0.87 | 60% | 0.520 |
| NOS Score | 1.02 (0.75–1.38) | 0.92 | 56% | 0.807 |
| C versus T | ||||
| Overall | 1.06 (0.96–1.18) | 0.26 | 25% | 0.915 |
| Asia | 1.06 (0.93–1.20) | 0.39 | 26% | 0.082 |
| America | 0.97 (0.76–1.25) | 0.84 | 42% | 0.384 |
| Rome II | 1.14 (0.97–1.33) | 0.11 | 17% | 0.094 |
| Rome III | 1.01 (0.87–1.16) | 0.93 | 31% | 0.190 |
| PCR-RFLP | 1.16 (0.97–1.38) | 0.10 | 43% | 0.884 |
| HWE | 1.04 (0.93–1.17) | 0.47 | 0 | 0.934 |
| IBS | 1.05 (0.94–1.17) | 0.40 | 30% | 0.730 |
| NOS Score | 1.06 (0.94–1.19) | 0.37 | 24% | 0.435 |
HWE, Hardy-Weinberg equilibrium; IBS, irritable bowel syndrome; PCR-RFLP, polymerase chain reaction-restriction fragment-length polymorphism; NOS, Newcastle-Ottawa Scale.
Figure 3Forest plot of the associations between GNB3 C825T polymorphism and FD risk under additive model based on PCR-RFLP genotyping method.